Premium
Comparative study of two antihypertensive agents: guanfacine and guanethidine.
Author(s) -
Szam I.,
Kallay K.
Publication year - 1980
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1980.tb04912.x
Subject(s) - guanfacine , guanethidine , medicine , orthostatic vital signs , blood pressure , diuretic , anesthesia , heart rate , placebo , antihypertensive drug , furosemide , clonidine , alternative medicine , pathology , stimulation
1. The antihypertensive effect and side‐effects of the new centrally acting agent guanfacine (BS 100‐141, Estulic) and guanethidine (Ismelin) were compared in a single‐blind, cross‐over study. The study consisted of two active treatment periods of 6 weeks each, both preceded by a 1‐3 weeks placebo period. 2. Sixteen ambulant patients (six male, ten female) with mild or moderate hypertension were admitted to the study. The patients were also receiving diuretic therapy (clopamide 10‐20 mg daily). On average the optimal daily dose of guanfacine was 3 mg and of guanethidine 20 mg. 3. An equally large and significant decrease in blood pressure was produced by both drugs. Both guanfacine and guanethidine caused a very slight reduction in heart rate. Mild orthostatic hypotension occurred in 11 patients during guanethidine therapy. Dryness of the mouth occurred in 13 patients taking guanfacine.